• 

  미림진, 패혈증 테라노스틱스 연구결과 글로벌 학술지 게재 / MirimGENE, Sepsis Theranostics research results published in global academic journals

  December 18, 2023

  We expect to present an innovative alternative that can increase the survival rate of septic shock.” Mirim Jin (CEO MirimGENE) announced on the 18th that the results of sepsis theranostics targeting WARS1 were published in the world-renowned medical journal 'EMBO Molecular Medicine (IF=14.005)' (title: 'Highly secreted tryptophanyl-tRNA synthetase as...

  READ MORE >
• 

  미림진, 진미림 대표 여성생명과학기술포럼 심포지엄 강연 / MirimGENE’ CEO, 22nd Women’s Bioscience Forum Symposium Presentation

  September 21, 2023

  Dr. Mirim Jin, the CEO, was in attendance at the Women’s Bioscience Forum (WBF) Symposium (22nd), which took place on September 21st, and delivered a presentation.   

  READ MORE >
• 

  미림진, "WARS1 타깃 자가면역질환 치료제 개발…내년 하반기 비임상 진입" / MirimGENE "Development of WARS1-targeted autoimmune disease therapy, launch of pre-clinical trials in the second half of next year."

  August 17, 2023

  CEO Mirim Jin conducted an interview with HitNews on the topic of “MirimGENE's core pipeline status and future blueprint.""We will leap forward as a biotech that leads the development of innovative new drugs (first-in-class) that can save the lives of autoimmune disease patients around the world. Currently, the manufacturing process (CMC) stage of the lead pipeline (new drug candida...

  READ MORE >
• 

  미림진, BIO USA 2023 참가 / MirimGENE, at BIO USA 2023

  June 15, 2023

  MirimGENE attended BIO USA 2023 in Boston from June 5th to 8th and was chosen as the presenting company at BIO USA 2023.MirimGENE was also able to connect with numerous global companies such as Novartis, Merck, Pfizer and present our science and technology to them.   

  READ MORE >
• 

  미림진, 중기부 아기유니콘 선정 / MirimGENE, MSS's 'Baby Unicorn' designation

  May 30, 2023

  On Tuesday, May 30, the Ministry of SMEs and Startups selected 51 ‘Baby Giant Startups (Unicorns)’ that have a high potential to grow into global giant startups (Unicorns). MirimGENE is designated as one of the finalist for Ministry of SMEs and Startups' Baby Unicorn.  source : https://mss.go.kr/site/smba/ex/bbs/View.do?cbIdx=86&bcIdx=1042056&parentSeq=1042056&n...

  READ MORE >
• 

  미림진, KDRA 바이오 혁신기업 포스터존에 참가 / MirimGENE, Participated in the KDRA Bio innovative companies poster zone.

  May 16, 2023

  MirimGENE participated in KDRA Bio innovative companies poster zone for the promotion of bio-venture, start-ups, universities, and lab's technologies in part of "KOREA PHARM & BIO 2023", the largest domestic pharm·bio-health industry fair and introduced the excellent Rheumatoid Arthritis treatment effect of WARS1 Neutralizing antibody.    

  READ MORE >